Next Post

Cingulate Inc. Reports First Quarter 2022 Results and Provides Clinical and Business Update

Cingulate Inc. Announcement of First Dosage for Anxiety Candidate CTx-2103 to Extend the Application of the Precision Timed Release™ Platform (PTR™) KANSAS CITY, Kan., May 12, 2022 (GLOBE NEWSWIRE) — Cingulate Inc. (NASDAQ: CING), a clinical-stage biopharmaceutical company utilizing its proprietary Precision Timed Release™ (PTR™) drug delivery platform technology to […]